You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • SAT0402 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of A Phase 3, Randomized, Controlled Trial (PALACE 1)

Citation Tools

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Poster Presentations. Psoriatic arthritis
SAT0402 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of A Phase 3, Randomized, Controlled Trial (PALACE 1)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Schafer P, Chen P, Fang L, et al
SAT0402 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of A Phase 3, Randomized, Controlled Trial (PALACE 1)
Annals of the Rheumatic Diseases 2014;73:739-740.